Donald J. McGuire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Donald J. McGuire has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Haydn T. Kissick
Emory Vaccine Center, Emory University School of Medicine, Atlanta, USA
12 shared publications - Rafi Ahmed
Emory Vaccine Center, Emory University School of Medicine
12 shared publications - Daniel Y. Chang
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA
11 shared publications - Maria Andrea Cardenas
Department of Urology, Emory University School of Medicine, Atlanta, USA
10 shared publications - Rustom Antia
Department of Biology, Emory University, Atlanta, Georgia, USA
10 shared publications - Ananya Saha
Emory University 2 Department of Biology Atlanta, GA
9 shared publications
Latest Publications
- 27 February 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (3) , 432-444
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial
Cabozantinib is an oral multikinase inhibitor approved for treatment in metastatic renal cell carcinoma (RCC). We conducted a phase 2, nonrandomized, single-arm clinical trial (NCT04022343) of cabozantinib treatment for 12 weeks in 17 patients with locally advanced, biopsy-proven, nonmetastatic clear cell RCC before surgical resection. The primary end point was the objective response rate (complete and partial responses) at week 12 and secondary end points included safety, tolerability, clinical and surgical outcomes, and quality of life. Six patients (35%) experienced a partial response and 11 patients (65%) had stable disease. The most common adverse events were diarrhea (n = 12, 70.6%), anorexia, fatigue and hypertension (n = 10, 58.8%), nausea and palmar-plantar erythrodysesthesia syndrome (n = 9, 52.9%). No treatment grade 4 or 5 adverse events related to cabozantinib or surgery occurred. The 1-year disease-free survival and overall survival were 82.4% (95% CI 54.7–93.9%) and 94.1% (95% CI 65–99.1%), respectively. Cabozantinib treatment activated CD8+ T cells in the blood, depleted myeloid populations and induced immune niches for TCF1+ stem-like CD8+ T cells. Cabozantinib was clinically active and safe in the neoadjuvant setting in patients with locally advanced nonmetastatic clear cell RCC.
- 27 February 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (3) , 432-444
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial
Cabozantinib is an oral multikinase inhibitor approved for treatment in metastatic renal cell carcinoma (RCC). We conducted a phase 2, nonrandomized, single-arm clinical trial (NCT04022343) of cabozantinib treatment for 12 weeks in 17 patients with locally advanced, biopsy-proven, nonmetastatic clear cell RCC before surgical resection. The primary end point was the objective response rate (complete and partial responses) at week 12 and secondary end points included safety, tolerability, clinical and surgical outcomes, and quality of life. Six patients (35%) experienced a partial response and 11 patients (65%) had stable disease. The most common adverse events were diarrhea (n = 12, 70.6%), anorexia, fatigue and hypertension (n = 10, 58.8%), nausea and palmar-plantar erythrodysesthesia syndrome (n = 9, 52.9%). No treatment grade 4 or 5 adverse events related to cabozantinib or surgery occurred. The 1-year disease-free survival and overall survival were 82.4% (95% CI 54.7–93.9%) and 94.1% (95% CI 65–99.1%), respectively. Cabozantinib treatment activated CD8+ T cells in the blood, depleted myeloid populations and induced immune niches for TCF1+ stem-like CD8+ T cells. Cabozantinib was clinically active and safe in the neoadjuvant setting in patients with locally advanced nonmetastatic clear cell RCC.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis, the one-way ANOVA test was used; total numbers were Log10 transformed. Bars represent mean and SEM. *p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis, the one-way ANOVA test was used; total numbers were Log10 transformed. Bars represent mean and SEM. *p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis, the one-way ANOVA test was used; total numbers were Log10 transformed. Bars represent mean and SEM. *p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
(A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis, the one-way ANOVA test was used; total numbers were Log10 transformed. Bars represent mean and SEM. *p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.
- Open Access
- 22 November 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (9) , 1833-1845
Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Purpose: Combination of chemotherapy with programmed cell death 1 (PD-1) blockade is a front-line treatment for lung cancer. However, it remains unknown whether and how chemotherapy affects the response of exhausted CD8 T cells to PD-1 blockade. Experimental Design: We used the well-established mouse model of T-cell exhaustion with chronic lymphocytic choriomeningitis virus (LCMV) infection to assess the effect of chemotherapy (cisplatin+pemetrexed) on T-cell response to PD-1 blockade, in the absence of the impact of chemotherapy on antigen release and presentation observed in tumor models. Results: When concomitantly administered with PD-1 blockade, chemotherapy affected the differentiation path of LCMV-specific CD8 T cells from stem-like to transitory effector cells, thereby reducing their expansion and production of IFNγ. After combination treatment, these restrained effector responses resulted in impaired viral control, compared with PD-1 blockade alone. The sequential combination strategy, where PD-1 blockade followed chemotherapy, proved to be superior to the concomitant combination, preserving the proliferative response of exhausted CD8 T cells to PD-1 blockade. Our findings suggest that the stem-like CD8 T cells themselves are relatively unaffected by chemotherapy partly because they are quiescent and maintained by slow self-renewal at the steady state. However, upon the proliferative burst mediated by PD-1 blockade, the accelerated differentiation and self-renewal of stem-like cells may be curbed by concomitant chemotherapy, ultimately resulting in impaired overall CD8 T-cell effector functions. Conclusions: In a translational context, we provide a proof-of-concept to consider optimizing the timing of chemo-immunotherapy strategies for improved CD8 T-cell functions. See related commentary by Vignali and Luke, p. 1705
- 22 November 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (9) , 1833-1845
Open AccessPlatinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade
Purpose: Combination of chemotherapy with programmed cell death 1 (PD-1) blockade is a front-line treatment for lung cancer. However, it remains unknown whether and how chemotherapy affects the response of exhausted CD8 T cells to PD-1 blockade. Experimental Design: We used the well-established mouse model of T-cell exhaustion with chronic lymphocytic choriomeningitis virus (LCMV) infection to assess the effect of chemotherapy (cisplatin+pemetrexed) on T-cell response to PD-1 blockade, in the absence of the impact of chemotherapy on antigen release and presentation observed in tumor models. Results: When concomitantly administered with PD-1 blockade, chemotherapy affected the differentiation path of LCMV-specific CD8 T cells from stem-like to transitory effector cells, thereby reducing their expansion and production of IFNγ. After combination treatment, these restrained effector responses resulted in impaired viral control, compared with PD-1 blockade alone. The sequential combination strategy, where PD-1 blockade followed chemotherapy, proved to be superior to the concomitant combination, preserving the proliferative response of exhausted CD8 T cells to PD-1 blockade. Our findings suggest that the stem-like CD8 T cells themselves are relatively unaffected by chemotherapy partly because they are quiescent and maintained by slow self-renewal at the steady state. However, upon the proliferative burst mediated by PD-1 blockade, the accelerated differentiation and self-renewal of stem-like cells may be curbed by concomitant chemotherapy, ultimately resulting in impaired overall CD8 T-cell effector functions. Conclusions: In a translational context, we provide a proof-of-concept to consider optimizing the timing of chemo-immunotherapy strategies for improved CD8 T-cell functions. See related commentary by Vignali and Luke, p. 1705